Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA,Spain,March 5,2025-- LaminarPharma,a leader in the development of innovative cancer therapy based on membrane lipid therapy,announced today optimistic results from its ongoing clini